Literature DB >> 7196300

Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy.

S E Epstein, D R Rosing.   

Abstract

Verapamil is extremely effective in the treatment of patients with hypertrophic cardiomyopathy. However, the basic physiologic actions of the drug may lead to serious adverse effects. An appreciation of this and an understanding of when these adverse effects are most likely to occur will minimize the potential of verapamil to cause serious complications in patients with hypertrophic cardiomyopathy.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7196300     DOI： 10.1161/01.cir.64.3.437

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


  29 in total

Review 1.  Medical treatment of hypertrophic cardiomyopathy.

Authors:  M V Sherrid; D Gunsburg; A Sharma
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

Review 2.  Problems in diagnosis and management of hypertrophic cardiomyopathy.

Authors:  O Odemuyiwa; W J McKenna
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

Review 3.  Calcium antagonists--adverse drug interactions.

Authors:  H Reicher-Reiss; H N Neufeld; F X Ebner
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

4.  Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression.

Authors:  A L Caforio; J H Goldman; M K Baig; A J Haven; L Dalla Libera; P J Keeling; W J McKenna
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

Review 5.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

6.  Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives.

Authors:  J B Marriott; J H Goldman; P J Keeling; M K Baig; A G Dalgleish; W J McKenna
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

Review 7.  Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.

Authors:  Daniel L Jacoby; Eugene C DePasquale; William J McKenna
Journal:  CMAJ       Date:  2012-10-29       Impact factor: 8.262

8.  Surgical management of hypertrophic cardiomyopathy in 2007: what is new?

Authors:  Morgan L Brown; Hartzell V Schaff
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

9.  Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.

Authors:  J Malcom; O Arnold; Jonathan G Howlett; Anique Ducharme; Justin A Ezekowitz; Martin J Gardner; Nadia Giannetti; Haissam Haddad; George A Heckman; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2008-01       Impact factor: 5.223

10.  Verapamil: a cause of sudden death in a patient with hypertrophic cardiomyopathy.

Authors:  B Perrot; N Danchin; A Terrier de la Chaise
Journal:  Br Heart J       Date:  1984-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.